Advances in Uveal Melanoma

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults and is associated with a high risk of metastasis and mortality. Over the past decade, major advances have been made in our understanding of UM biology, including the identification of Gαq/11 pathway mutations as key oncogenic drivers and the recognition of BAP1 and SF3B1 mutations as important molecular determinants of tumor metastatic risk. Advances in technology also resulted in two treatments being approved by the US FDA, namely T-cell engager, tebemtafusp-tebn (Kimmtrak™), and percutaneous hepatic perfusion with HEPZATO KIT™ (melphalan for injection/hepatic delivery system). These approaches significantly expanded the therapeutic landscape for metastatic uveal melanoma (MUM).   This Special Issue in Cancers, entitled “Advances in Uveal Melanoma,” aims to highlight recent advances in the understanding and treatment of UM, including, but not limited to, studies addressing UM biological mechanisms, clinical outcomes of existing therapies, and future directions of treatment options. We hope this Special Issue will provide a comprehensive overview of recent progress and highlight new opportunities to improve outcomes for patients with uveal melanoma.